scispace - formally typeset
M

Mary C. Nakamura

Researcher at University of California, San Francisco

Publications -  91
Citations -  7149

Mary C. Nakamura is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Osteoclast & Receptor. The author has an hindex of 38, co-authored 82 publications receiving 5709 citations. Previous affiliations of Mary C. Nakamura include Mount Sinai Hospital & Veterans Health Administration.

Papers
More filters
Journal ArticleDOI

The immunomodulatory adapter proteins DAP12 and Fc receptor γ-chain (FcRγ) regulate development of functional osteoclasts through the Syk tyrosine kinase

TL;DR: Data indicate that recruitment of Syk to phosphorylated ITAMs is critical for osteoclastogenesis, which provides new insight into the biology of osteoclasts and suggest novel therapeutic targets in diseases of bony remodeling.
Journal ArticleDOI

Binding and uptake of H-ferritin are mediated by human transferrin receptor-1

TL;DR: The demonstration that TfR1 can bind HFt as well as Tf raises the possibility that this dual receptor function may coordinate the processing and use of iron by these iron-binding molecules.
Journal ArticleDOI

Cutting Edge: Inhibition of TLR and FcR Responses in Macrophages by Triggering Receptor Expressed on Myeloid Cells (TREM)-2 and DAP12

TL;DR: It is shown that Triggering Receptor Expressed on Myeloid cells (TREM)-2 is responsible for the DAP12-mediated inhibition in mouse macrophages and the interaction of TREM-2 and its ligand results in an inhibitory signal that can reduce the inflammatory response.
Journal ArticleDOI

A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia.

TL;DR: It is demonstrated that TREM2 interacts with endogenous ligands on neurons, forming a receptor–ligand pair connecting microglia with apoptotic neurons, directing removal of damaged cells to allow repair.
Journal ArticleDOI

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

TL;DR: In this article, the authors developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions to develop updated guidelines for the pharmacologic management of rheumatoid arthritis.